Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. Addiction. 2017;112(10):1725–39. https://doi.org/10.1111/add.13877.
Article
PubMed
PubMed Central
Google Scholar
Binswanger IA. Opioid use disorder and incarceration: hope for ensuring the continuity of treatment. N Engl J Med. 2019;380(13):1193.
PubMed
Google Scholar
Tsai J, Gu X. Utilization of addiction treatment among US adults with history of incarceration and substance use disorders. Addict Sci Clin Pract. 2019;14(1):9.
PubMed
PubMed Central
Google Scholar
Bi-Mohammed Z, Wright NM, Hearty P, King N, Gavin H. Prescription opioid abuse in prison settings: a systematic review of prevalence, practice and treatment responses. Drug Alcohol Depend. 2017;171:122–31.
PubMed
Google Scholar
Cope N. Drug use in prison: the experience of young offenders. Drugs. 2000;7(4):355–66.
Google Scholar
Connor DP, Tewksbury R. Inmates and prison involvement with drugs: examining drug-related misconduct during incarceration. J Contemp Crim Justice. 2016;32(4):426–45.
Google Scholar
Carpentier C, Royuela L, Montanari L, Davis P. The global epidemiology of drug use in prison. In: Drug use in prisoners: epidemiology, implications, and policy responses. New York: Oxford University Press; 2018. p. 17–41.
Google Scholar
Ternes M, Johnson S. Substance abuse problem severity, treatment readiness, and response bias among incarcerated men. Ottawa: Correctional Service Canada; 2014. Retrieved from:http://www.csc-scc.gc.ca/005/008/092/rs13-05-eng.pdf
Google Scholar
Mullins P, Ternes M, Farrell MacDonald S. Substance use on day of offence in a sample of male federal offenders. Ottawa: Correctional Service Canada; 2013. Retrieved from:http://www.csc-scc.gc.ca/research/005008-rs13-01-eng.shtml
Google Scholar
Garrel S, Farrell MacDonald S. Substance use patterns of men offenders: an ethnocultural comparison. Ottawa: Correctional Service Canada; 2019. Retrieved from:https://www.csc-scc.gc.ca/research/rib-20-04-en.shtml
Google Scholar
Farrell MacDonald S, MacSwain M-A, Cheverie M, Tiesmaki M, Fischer B. Impact of methadone maintenance treatment on women offenders’ post-release recidivism. Eur Addict Res. 2014;20(4):192–9.
PubMed
Google Scholar
Canadian Institutes for Health Information (CIHI). Proposed standards for race-based and Indigenous identity and data collection and health reporting in Canada: Toronto, Ontario Canadian Institutes for Health Information (CIHI); 2020. Retrieved from:https://www.cihi.ca/sites/default/files/document/proposed-standard-for-race-based-data-en.pdf
Google Scholar
Farrell MacDonald S, Gobeil R, Biro SM, Ritchie MB, Curno J. Women offenders, substance use, and behavior. Ottawa: Correctional Service Canada; 2016. Retrieved from:https://www.csc-scc.gc.ca/research/005008-r358-eng.shtml
Google Scholar
Farrell MacDonald S. Comparing substance use patterns of aboriginal and Non-aboriginal women offenders. Ottawa: Correctional Service Canada; 2014. Retrieved from:https://www.csc-scc.gc.ca/005/008/092/rs14-26-eng.pdf
Google Scholar
Cram S, Farrell-Macdonald S. Comparison of women offenders who use opioids versus other types of substances. Ottawa: Correctional Service Canada; 2019. Retrieved from:https://www.csc-scc.gc.ca/005/008/092/rib-19-09-en.pdf
Google Scholar
Kouyoumdjian F, Calzavara LM, Kiefer L, Main C, Bondy SJ. Drug use prior to incarceration and associated socio-behavioural factors among males in a provincial correctional facility in Ontario, Canada. Can J Public Health. 2014;105(3):e198–202.
PubMed
PubMed Central
Google Scholar
Johnson S, Farrell MacDonald S, Cheverie M, Myrick C, Fischer B. Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada. Drug Alcohol Depend. 2012;124(1–2):172–6.
PubMed
Google Scholar
MacSwain MA, Farrell MacDonald S, Cheverie M, Fischer B. Assessing the impact of methadone maintenance treatment (mmt) on post-release recidivism among male federal correctional inmates in Canada. Crim Justice Behav. 2014;41(3):380–94.
Google Scholar
McKendy L, Biro S, Keown LA: Overdose Incidents in cederal Custody, 2012/2013–2016/2017. 2018. Ottawa, Ontario Correctional Service Canada. Retrieved from:https://www.csc-scc.gc.ca/research/092/sr-18-02-en.pdf
Correctional Service Canada. Guidance on opioid agoinst treatment (OAT). Ottawa: Correctional Service Canada; 2020. Retrieved from:https://www.csc-scc.gc.ca/health/002006-3004-en.shtml?wbdisable=true
Google Scholar
Bruneau J, Ahamad K, Goyer M-È, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190(9):E247–57.
Google Scholar
Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009;10(11):1727–40.
CAS
PubMed
PubMed Central
Google Scholar
Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3.
PubMed
Google Scholar
Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people: John Wiley & Sons, Ltd; 2016. Retrieved from:http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011117.pub2/abstract
Google Scholar
Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979–93.
PubMed
Google Scholar
Lines R. From equivalence of standards to equivalence of objectives: the entitlement of prisoners to health care standards higher than those outside prisons. Int J Prison Health. 2006;2(4):269–80.
Google Scholar
Brezel ER, Powell T, Fox AD. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated. Subst Abus. 2020;41(2):150–4.
PubMed
Google Scholar
United Nations Office on Drugs and Crime (UNODC). The United Nations standard minimum rules for the treatment of prisoners (The Nelson Mandela Rules). Vienna: United Nations Office on Drugs and Crime (UNODC); 2015. Retrieved from:https://www.unodc.org/documents/justice-and-prison-reform/GA-RESOLUTION/E_ebook.pdf
Google Scholar
Sander G, Shirley-Beavan S, Stone K. The global state of harm reduction in prisons. J Correct Health Care. 2019;25(2):105–20.
PubMed
Google Scholar
Bone C, Eysenbach L, Bell K, Barry DT. Our ethical obligation to treat opioid use disorder in prisons: a patient and physician's perspective. J Law Med Ethics. 2018;46(2):268–71.
PubMed
Google Scholar
Grella CE, Ostile E, Scott CK, Dennis M, Carnavale J. A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system. Int J Drug Policy. 2020;81:102768.
PubMed
PubMed Central
Google Scholar
Hedrich D, Alves P, Farrell M, Stöver H, Møller L, Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501–17.
PubMed
Google Scholar
Kouyoumdjian FG, Patel A, To MJ, Kiefer L, Regenstreif L. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: a survey. PLoS One. 2018;13(2):e0192431.
PubMed
PubMed Central
Google Scholar
Vestal C. At Rikers Island, a legacy of medication-assisted opioid treatment. New York: The PEW Charitable Trusts; 2016. Retrieved from:https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2016/05/23/at-rikers-island-a-legacy-of-medication-assisted-opioid-treatment
Google Scholar
Sharma A, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Schwartz RP. Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Subst Abus Rehabil. 2016;7:27–40.
Google Scholar
Wakeman SE, Rich JD. Addiction treatment within U.S. correctional facilities: bridging the gap between current practice and evidence-based care. J Addict Dis. 2015;34(2/3):220–5.
PubMed
Google Scholar
Komalasari R, Wilson S, Haw S. A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in PRISONS. Int J Drug Policy. 2021;87:102978.
PubMed
Google Scholar
Brinkley-Rubinstein L, Cloud DH, Davis C, Zaller N, Delany-Brumsey A, Pope L, et al. Addressing excess risk of overdose among recently incarcerated people in the USA: harm reduction interventions in correctional settings. Int J Prison Health. 2017;13(1):25–31.
PubMed
Google Scholar
Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after federal oversight. Can J Psychiatry. 2017;62(7):444–50.
PubMed
PubMed Central
Google Scholar
Johnson S, van de Ven JTC, Grant BA. Institutional methadone maintenance treatment: Impact on release outcome and institutional behaviour. Ottawa: Correctional Service Canada; 2001. Retrieved from:http://www.csc-scc.gc.ca/text/rsrch/reports/r119/r119_e.pdf
Google Scholar
MacSwain MA, Cheverie M. Comparing the mental health treatment and abuse histories of men and women methadone maintenance treatment program (MMTP) participants. Ottawa: Correctional Service Canada; 2012. Retrieved from:http://www.csc-scc.gc.ca/research/005008-rs12-9-eng.shtml
Google Scholar
MacSwain MA, Farrell MacDonald S, Cheverie M, Fischer B. Assessing the impact of methadone maintenance treatment (MMT) on post-release recidivism among male federal correctional inmates in Canada. Crim Justice Behav. 2013;41(3):380–94.
Google Scholar
Correctional Service Canada. CSC Statistics - Key Facts and Figures. Ottawa: Government of Canada; 2017. Retrieved from:http://www.csc-scc.gc.ca/publications/005007-3024-eng.shtml
Google Scholar
Lanoie LO. Opioid substitution therapy in Canada's prisons. Can J Addict. 2015;6(3):5–7.
Google Scholar
Correctional Service Canada. Opioids. Ottawa: Correctional Service Canada; 2019. Retrieved from:https://mail.google.com/mail/ca/u/0/#inbox
Google Scholar
Correctional Service Canada. Opioid Agonist Treatment. Ottawa: Correctional Service Canada; 2021. Retrieved from:https://www.csc-scc.gc.ca/health/002006-3000-en.shtml
Google Scholar
Perry AE, Neilson M, James M-S, Glanville JM, Woodhouse R, Godfrey C, et al. Pharmacological interventions for drug-using offenders. Cochrane Database Syst Rev. 2015;6:CD010862.
Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions, and outcomes among incarcerated persons: a systematic review. PLoS Med. 2019;16(12):e1003002.
PubMed
PubMed Central
Google Scholar
Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abus Treat. 2019;99:32–43.
Google Scholar
Green TC, Clarke J, Brinkley-Rubinstein L, Marshall BDL, Alexander-Scott N, Boss R, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–7.
PubMed
PubMed Central
Google Scholar
Bozinoff N, DeBeck K, Milloy MJ, Nosova E, Fairbairn N, Wood E, et al. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada. Drug Alcohol Depend. 2018;193:42–7.
CAS
PubMed
PubMed Central
Google Scholar
Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018;113(4):656–67.
PubMed
Google Scholar
Correctional Service Canada. Evaluation Report: CSC's Health Services. Ottawa: Correctional Service Canada (CSC); 2017. Retrieved from:https://www.csc-scc.gc.ca/publications/092/005007-2017-eng.pdf
Google Scholar
McKenzie M, Nunn A, Zaller ND, Bazazi AR, Rich JD. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manag. 2009;5(4):219–27.
PubMed
PubMed Central
Google Scholar
Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–8.
CAS
PubMed
PubMed Central
Google Scholar
Fiscella K, Moore A, Engerman J, Meldrum S. Jail management of arrestees/inmates enrolled in community methadone maintenance programs. J Urban Health. 2004;81(4):645.
PubMed
PubMed Central
Google Scholar
Binswanger IA, Nowels C, Corsi KF, Long J, Booth RE, Kutner J, et al. “From the prison door right to the sidewalk, everything went downhill,” a qualitative study of the health experiences of recently released inmates. Int J Law Psychiatry. 2011;34(4):249–55.
PubMed
Google Scholar
Larney S, Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Eur Addict Res. 2009;15(2):107–12.
PubMed
Google Scholar
Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, et al. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018;86:104–10.
PubMed
Google Scholar
Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357.
Correctional Service Canada. Commissioner's Directives 009 Research. Ottawa: Correctional Service Canada; 2017. Retrieved from:https://www.csc-scc.gc.ca/lois-et-reglements/009-cd-en.shtml
Google Scholar
Correctional Service Canada. The Offender Management System. Ottawa: Correctional Service Canada; 2013. Retrieved from:https://www.csc-scc.gc.ca/oms/004003-0001-eng.shtml
Google Scholar
Correctional Service Canada. Commissioner’s Directive 705-6: Correctional planning and criminal profile. Ottawa: Correctional Service Canada; 2018. Retrieved from: https://www.csc-scc.gc.ca/acts-and-regulations/705-6-cd-en.shtml
Google Scholar
Motiuk L, Vuong B. Development and validation of a criminal risk index (CRI) for federally sentenced offenders in Canada. Ottawa: Correctional Service of Canada; 2018. Retrieved from: https://www.csc-scc.gc.ca/research/r-403-en.shtml
Google Scholar
Kunic D, Grant BA. The computerized assessment of substance abuse (CASA): Results from the demonstration project. Ottawa: Correctional Service Canada; 2006. Retrieved from:https://www.csc-scc.gc.ca/research/r173-eng.shtml
Google Scholar
Creswell JW, Creswell JD. Research design: qualitative, quantitative, and mixed methods approaches: Sage publications; 2017.
Google Scholar
Williams M, Moser T. The art of coding and thematic exploration in qualitative research. Int Manag Rev. 2019;15(1):45–55.
Google Scholar
O’Connor C, Joffe H. Intercoder reliability in qualitative research: debates and practical guidelines. Int J Qual Methods. 2020;19:1609406919899220.
Google Scholar
Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–907.
PubMed
Google Scholar
Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):14008.
Google Scholar
Fazel S, Hayes AJ, Bartellas K, Clerici M, Trestman R. Mental health of prisoners: prevalence, adverse outcomes, and interventions. Lancet Psychiatry. 2016;3(9):871–81.
PubMed
PubMed Central
Google Scholar
Department of Justice Canada. Spotlight on Gladue: challenges, experiences, and possibilities in Canada's criminal justice system. Ottawa: Government of Canada; 2019. Retrieved from:https://www.justice.gc.ca/eng/rp-pr/jr/gladue/p2.html
Google Scholar
Boyd S, MacPherson D. Vancouver area network of drug users: community engagement - the harms of drug prohibition: ongoing resistance in Vancouver’s downtown eastside. BC Stud. 2019;200:87–96.
Google Scholar
Fischer B. Prohibition, public health and a window of opportunity: an analysis of Canadian drug policy, 1985-1997. Policy Stud. 1999;20(3):197–210.
Google Scholar
Monico L, Gryczynski J, Lee JD, Dusek K, McDonald R, Malone M, et al. Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration. J Subst Abus Treat. 2020;108267.
Bucerius SM, Haggerty KD. Fentanyl behind bars: the implications of synthetic opiates for prisoners and correctional officers. Int J Drug Policy. 2019;71:133–8.
PubMed
Google Scholar
van der Meulen E. “It goes on everywhere”: injection drug use in Canadian federal prisons. Subst Use Misuse. 2017;52(7):884–91.
PubMed
Google Scholar
Ahmed R, Angel C, Martel R, Pyne D, Keenan L. Access to healthcare services during incarceration among female inmates. Int J Prison Health. 2016;12(4):204–15.
PubMed
Google Scholar
Plugge E, Douglas N, Fitzpatrick R. Patients, prisoners, or people? Women prisoners’ experiences of primary care in prison: a qualitative study. Br J Gen Pract. 2008;58(554):e1–8.
PubMed Central
Google Scholar
Fiscella K, Wakeman SE, Beletsky L. Implementing opioid agonist treatment in correctional facilities. JAMA Intern Med. 2018;178(9):1153–4.
PubMed
Google Scholar
West Coast Prison Justice Society. West Coast Prison Justice Society files human rights complaint against Correctional Service Canada on behalf of federal prisoners with opioid use disorder. Vancouver: West Coast Prison Justice Society (WCPJS); 2018. Retrieved from:https://prisonjustice.org/wp-content/uploads/2018/12/OST-rep-complaint-to-CHRC-20180604-narrative-1.pdf
Google Scholar
The College of Physicians and Surgeons of Ontario. Methadone maintenance treatment: Program standards and clinical guidelines. Toronto: College of Physicians and Surgeons of Ontario; 2011. Retrieved from:http://www.cpso.on.ca/uploadedFiles/members/MMT-Guidelines.pdf
Google Scholar
Csete J. Criminal justice barriers to treatment of opioid use disorders in the United States: the need for public health advocacy. Am J Public Health. 2019;109(3):419–22.
PubMed
PubMed Central
Google Scholar
The Lancet Public H. A public health approach to Canada's opioid crisis. Lancet Public Health. 2018;3(5):e204.
Google Scholar
Gryczynski J, Jaffe JH, Schwartz RP, Dušek KA, Gugsa N, Monroe CL, et al. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013;22(3):285–91.
PubMed
PubMed Central
Google Scholar
Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, et al. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014;46(5):412–26.
PubMed
PubMed Central
Google Scholar
Schwartz RP, Kelly SM, O'Grady KE, Mitchell SG, Peterson JA, Reisinger HS, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008;17(5):396–401.
PubMed
PubMed Central
Google Scholar
Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2.
PubMed
PubMed Central
Google Scholar
Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addict Sci Clin Pract. 2019;14(1):37.
PubMed
PubMed Central
Google Scholar
Wakeman SE, Rich JD. Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction. J Gen Intern Med. 2017;32(1):17–9.
PubMed
Google Scholar
Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330–3.
PubMed
Google Scholar
Davis EL, Kelly PJ, Deane FP, Baker AL, Buckingham M, Degan T, et al. The relationship between patient-centered care and outcomes in specialist drug and alcohol treatment: a systematic literature review. Subst Abus. 2020;41(2):216–31.
PubMed
Google Scholar
Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7.
PubMed
PubMed Central
Google Scholar
Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(1):37.
PubMed
PubMed Central
Google Scholar
Trujols J, González-Saiz F, Manresa MJ, Alcaraz S, Batlle F, Duran-Sindreu S, et al. Patient perception of methadone dose adequacy in methadone maintenance treatment: the role of perceived participation in dosage decisions. Patient Educ Couns. 2017;100(5):981–6.
PubMed
Google Scholar
Larney S, Dolan K. Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care. Aust N Z J Public Health. 2008;32(1):86–7.
PubMed
Google Scholar
Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, et al. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). J Subst Abus Treat. 2021;128;108389.
Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, et al. What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opin Drug Deliv. 2019;16(9):907–14.
CAS
PubMed
Google Scholar
Gordon MS, Vocci FJ, Taxman F, Fishman M, Sharma B, Blue TR, et al. A randomized controlled trial of buprenorphine for probationers and parolees: bridging the gap into treatment. Contemp Clin Trials. 2019;79:21–7.
PubMed
PubMed Central
Google Scholar
Gordon MS, Vocci FJ, Fitzgerald TT, O'Grady KE, O'Brien CP. Extended-release naltrexone for pre-release prisoners: a randomized trial of medical mobile treatment. Contemp Clin Trials. 2017;53:130–6.
PubMed
Google Scholar
Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, et al. Managing opioid use disorder in primary care: PEER simplified guideline. Can Fam Physician. 2019;65(5):321–30.
PubMed
PubMed Central
Google Scholar
Bahji A, Carlone D, Altomare J. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis. Addiction. 2020;115(8):1413–25.
PubMed
Google Scholar
Tian EJ, Venugopalan S, Kumar S, Beard M. The impacts of and outcomes from telehealth delivered in prisons: a systematic review. Plos One. 2021;16(5):e0251840.
CAS
PubMed
PubMed Central
Google Scholar
Edge C, Black G, King E, George J, Patel S, Hayward A. Improving care quality with prison telemedicine: the effects of context and multiplicity on successful implementation and use. J Telemed Telecare. 2019;27(6):325–42.
PubMed
Google Scholar
Government of Canada: Opioid- and stimulant-related harms in Canada. 2020. Ottawa: Government of Canada. Retrieved from:https://health-infobase.canada.ca/substance-related-harms/opioids/maps?index=1
Krsak M, Montague BT, Trowbridge P, Johnson SC, Binswanger IA. Opioid use and chronic infections: The value of addressing the syndemic in correctional settings via telemedicine: Guidance and broader use of long-acting medications. J Infect Dis. 2020;222(Supplement_5):S486–93.
CAS
PubMed
Google Scholar
Caulkins JP, Gould A, Pardo B, Reuter P, Stein BD. Opioids and the criminal justice system: new challenges posed by the modern opioid epidemic. Annu Rev Crim. 2021;4(1):353–75.
Google Scholar
Gordon MS, Mitchell SG, Blue TR, Vocci FJ, Fishman MJ, Murphy SM, et al. A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail. J Subst Abus Treat. 2020;108241.
Gordon MS, Kinlock TW, Vocci FJ, Fitzgerald TT, Memisoglu A, Silverman B. A phase 4, pilot, open-label study of VIVITROL®(extended-release naltrexone XR-NTX) for prisoners. J Subst Abus Treat. 2015;59:52–8.
Google Scholar
Springer SA, Altice FL, Brown S-E, Di Paola A. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend. 2015;157:158–65.
PubMed
PubMed Central
Google Scholar
Schwartz RP, Mitchell MM, O'Grady KE, Kelly SM, Gryczynski J, Mitchell SG, et al. Pharmacotherapy for opioid addiction in community corrections. Int Rev Psychiatry. 2018;30(5):117–35.
PubMed
PubMed Central
Google Scholar
Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction. 2015;110(6):1008–14.
PubMed
Google Scholar
Correctional Service Canada. Opioid agonist treatment. Ottawa: Correctional Service Canada; 2019. Retrieved from:https://www.csc-scc.gc.ca/health/002006-2007-en.shtml
Google Scholar
Correctional Service Canada. Promoting wellness and independence of older persons in CSC custody. A policy framework: Pain Management. Ottawa: Correctional Service Canada; 2018. Retrieved from:https://www.csc-scc.gc.ca/publications/005007-1601-en.shtml#6.8
Google Scholar
Binswanger IA, Nowels C, Corsi KF, Glanz J, Long J, Booth RE, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7(3).
Lee J, Gordon M, Friedmann P, Nunes E, O'Brien C. Extended-release naltrexone to prevent opioid relapse among adults with criminal justice system involvement. Am J Addict. 2016;25(4):345.
Google Scholar
Begun AL, Early TJ, Hodge A. Mental health and substance abuse service engagement by men and women during community reentry following incarceration. Adm Policy Ment Health Ment Health Serv Res. 2016;43(2):207–18.
Google Scholar
Martin RA, Gresko SA, Brinkley-Rubinstein L, Stein LAR, Clarke JG. Post-release treatment uptake among participants of the Rhode Island Department of Corrections comprehensive medication assisted treatment program. Prev Med. 2019;128:105766.
PubMed
Google Scholar
Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112–8.
CAS
PubMed
PubMed Central
Google Scholar
Canzater SL, LaBelle RM. Championing change to save lives: a call to action to implement reforms to increase use of medications to treat opioid use disorder in correctional settings. Crim Justice Rev. 2020;0(0):0734016820981629.
Google Scholar
Correctional Service Canada. Correctional programs. Ottawa: Correctional Service Canada; 2019. Retrieved from:https://www.csc-scc.gc.ca/002/002-0001-en.shtml
Google Scholar
Macmadu A, Rich JD. Correctional health is community health. Issues Sci Technol. 2015;32(1).
Beletsky L. Treating substance use and mental health disorders in correctional settings: Northeastern Univeristy of Law; 2019. Retrieved from:https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3499366
Google Scholar